Feil Family Brain & Mind Research Institute

Publications

Found 15 results
Author Title [ Type(Desc)] Year
Filters: Author is Vartanian, Timothy  [Clear All Filters]
Journal Article
Telesford KM, Kaunzner UW, Perumal J, Gauthier SA, Wu X, Díaz I, Kruse-Hoyer M, Engel C, Marcille M, Vartanian T.  2020.  Black African and Latino/a identity correlates with increased plasmablasts in MS.. Neurol Neuroimmunol Neuroinflamm. 7(1)
Linden JR, Ma Y, Zhao B, Harris JMichael, Rumah KRashid, Schaeren-Wiemers N, Vartanian T.  2015.  Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination.. MBio. 6(3):e02513.
Linden JR, Flores C, Schmidt EF, Uzal FA, Michel AO, Valenzuela M, Dobrow S, Vartanian T.  2019.  Clostridium perfringens epsilon toxin induces blood brain barrier permeability via caveolae-dependent transcytosis and requires expression of MAL.. PLoS Pathog. 15(11):e1008014.
Al-Kawaz M, Monohan E, Morris E, Perumal JS, Nealon N, Vartanian T, Gauthier SA.  2017.  Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.. J Neuroimaging. 27(3):333-338.
Ma Y, Sannino D, Linden JR, Haigh S, Zhao B, Grigg JB, Zumbo P, Dündar F, Butler DJ, Profaci CP et al..  2023.  Epsilon toxin-producing Clostridium perfringens colonize the MS gut and epsilon toxin overcomes immune privilege.. J Clin Invest.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.. Mult Scler. 24(4):540-542.
Pandya S, Kaunzner UW, Rúa SMHurtado, Nealon N, Perumal J, Vartanian T, Nguyen TD, Gauthier SA.  2020.  Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions.. J Neuroimaging. 30(4):537-543.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Vargas WS, Monohan E, Pandya S, Raj A, Vartanian T, Nguyen TD, Rúa SMHurtado, Gauthier SA.  2015.  Measuring longitudinal myelin water fraction in new multiple sclerosis lesions.. Neuroimage Clin. 9:369-75.
Rumah KRashid, Ma Y, Linden JR, Oo MLin, Anrather J, Schaeren-Wiemers N, Alonso MA, Fischetti VA, McClain MS, Vartanian T.  2015.  The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin.. PLoS Pathog. 11(5):e1004896.
Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.
Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, Balcer LJ, Markowitz CE, Vartanian T, Morrow M et al..  2015.  Re-evaluating the treatment of acute optic neuritis.. J Neurol Neurosurg Psychiatry. 86(7):799-808.
Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D et al..  2016.  Relapses in multiple sclerosis: Relationship to disability.. Mult Scler Relat Disord. 6:10-20.
Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T, Perumal JS.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. Mult Scler. 24(4):553-554.